Hsp90 Inhibitors Binding to Unique Pocket
Solution Overview
Problem
Current Hsp90 inhibitors exhibit variable activity with EC50 and IC50 values ranging from micromolar to nanomolar levels, necessitating the development of more potent compounds that can effectively target Hsp90 for therapeutic applications, particularly in cancer and neurodegenerative diseases.
Innovation Solution
The development of new compounds, specifically those represented by Formulas (IA) and (IB), which are designed to inhibit Hsp90 by binding to its unique pocket, featuring various structural components such as sulfonamido, sulfinamido, and amido groups, to achieve therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing Hsp90 inhibitors are used, then therapeutic effect is achieved, but the activity is variable with EC50 and IC50 values ranging from micromolar to nanomolar levels
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical structure parameters of Hsp90 inhibitors. Specifically, the invention changes the core structure from simple purine to fused amino pyridine systems with varying ring sizes (5-membered, 6-membered, or fused combinations), substitutes different functional groups at specific positions, and adjusts substituent types (halogen, alkyl, aryl, heteroaryl) to optimize binding affinity and reduce EC50/IC50 values from micromolar to nanomolar range
Solution Approach 2:
The patent employs composite materials principle by creating complex fused ring systems that combine multiple heterocyclic components. The inhibitors consist of fused amino pyridine cores integrated with additional ring structures (such as indole, benzofuran, thienopyridine), forming composite molecular architectures that enhance target binding affinity and therapeutic potency compared to simple purine structures
2Reliability
If more potent compounds are developed to achieve nanomolar activity, then therapeutic efficacy is improved, but compound complexity increases
Solution Approach 1:
The patent applies local quality principle by introducing specific functional groups and substituents at particular positions on the fused ring core structure. Different substituents (halogen at position 2, alkyl/aryl at position 6, specific amide/sulfonamide groups at position 9) are strategically placed to maximize binding affinity to specific pockets on Hsp90, achieving high potency without requiring excessive molecular complexity throughout the entire structure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate high binding affinity and therapeutic potential for inhibiting Hsp90, offering improved activity compared to existing inhibitors, making them suitable for treating cancer and neurodegenerative disorders.
Implementation Method 1
These compounds demonstrate high binding affinity and therapeutic potential for inhibiting Hsp90, offering improved activity compared to existing inhibitors
Data Source
AI summary
The disclosure relates to Compounds of Formulae (IA) and (IB), and pharmaceutically acceptable salts thereof wherein Z1, Z2, Z3, Xa, Xb, Xc, Xd, Y, X2, and X4 are as defined herein, compositions comprising an effective amount of a Compound of Formula (IA) and/or (IB), and methods to treat or prevent a condition, such cancer which overexpresses Her-kinases, comprising administering to an patient in need thereof a therapeutically effective amount of a Compound of Formula (IA) or (IB). The disclosure further relates to compounds of Formulae (IA) and (IB) in which X2 is a leaving for introducing a radiolabeled atom, such as 124I or 131I and to methods of using such compounds in the preparation of radiolabeled compounds, particularly for use in imaging.